Posted by Michael Wonder on 19 Jan 2024
Kyverna Therapeutics granted FDA fast track designation for KYV-101 in the treatment of patients with refractory progressive multiple sclerosis
19 January 2024 - The announcement follows the recent IND clearance for KYV-101 to be used in Kyverna's KYSA-7 Phase 2 open-label, multi-centre study.
Kyverna Therapeutics today announced it received fast track designation by the US FDA for its autologous, fully human CD19 chimeric antigen receptor T-cell product candidate, KYV-101, to be used for the treatment of multiple sclerosis.
